Chaoju Eye Care Holdings Limited reported that its total issued share capital remained unchanged at 701.46 million ordinary shares as of 7 October 2026, despite executing a share repurchase on the same day.

On 7 October 2026 the company bought back 185,000 shares on the Hong Kong Stock Exchange at prices ranging from HKD 2.365 to HKD 2.385 per share, for a total consideration of HKD 0.44 million. The transaction represents approximately 0.03% of the company’s existing issued shares (excluding treasury shares) prior to the repurchase. All repurchased shares are slated for cancellation.

Including this latest transaction, Chaoju Eye Care has repurchased 3.15 million shares between 31 August and 7 October 2026 that are pending cancellation—equivalent to about 0.45% of the current share base.

Under the general mandate approved on 12 May 2026, the company is authorised to repurchase up to 70.52 million shares. Cumulative on-exchange repurchases under this mandate now stand at 6.49 million shares, or 0.92% of the issued shares outstanding on the mandate date, leaving roughly 64.03 million shares available for further buybacks.

In line with Hong Kong Listing Rules, Chaoju Eye Care is subject to a moratorium on issuing new shares or disposing of treasury shares until 6 November 2026. The company confirmed that all repurchase activities complied with relevant regulatory requirements and were duly authorised by its board.